Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Penfluridol versus oral second-generation antipsychotics in psychotic disorders
NL-OMON44089Phase 3Withdrawn
- Sponsor
- Erasmus MC
- Start
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Schizophrenia Spectrum Disorders (SSD), schizophrenia, schizoaffective disorder and 2 more comparing Penfluridol once weekly, Olanzapine once daily and Risperidone once daily (3 arms). Primary endpoint: Time to all-cause discontinuation. Planned start Apr 2015; status: withdrawn.
02
Drugs
penfluridololanzapinerisperidone
03
Conditions
Schizophrenia Spectrum Disorders (SSD)schizophreniaschizoaffective disorderdelusional disorderUnspecified psychosis
Beyond the preview
Go deeper on NL-OMON44089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44089.